Epidemiology trends and progress in breast cancer survival: earlier diagnosis, new therapeutics

Abstract

Purpose of review In this review we will critically appraise the latest evidence on breast cancer (BC) survival trends and discuss how these may reflect breakthroughs in early diagnosis and treatment approaches. We will address the wide global inequalities in BC survival and review the ongoing initiatives aimed at improving cancer control worldwide. Recent findings BC outcomes have improved in high-income countries during the last decades, following the implementation of strategies for early detection and optimal multimodality treatment. Novel therapeutics, such as anti-HER2 targeted treatments, have also contributed to the progress in BC survival. However, BC mortality is still high in low-income countries, due to the lack of optimal healthcare infrastructures. In the context of marked inequities in BC management across world regions, international collaborations such as the Global Breast Cancer Initiative and the Global Initiative for Cancer Registry Development work to foster capacity-building in developing countries, tackle the burden of BC and deliver the Sustainable Development Goals by 2030. Summary Collection of robust, high-quality data from population-based cancer registries is crucial to drive and refine public health interventions. Population-based data are also the litmus paper to evaluate the real-world impact of clinical advances and monitor progress.

Dietary supplementation of pomegranate extract alters the Caspase-3 and VEGF promoter epigenetic methylation status and protein levels in breast cancer patients undergoing chemotherapy

“…Breast cancer is a global health problem and the most common cancer amongst women worldwide and in Egypt (Amato et al, 2023). Moreover, In terms of female cancer-associated death rates, BC ranks as the first (Siegel et al, 2023).…”

Assessment of Untargeted Metabolomics by Hydrophilic Interaction Liquid Chromatography−Mass Spectrometry to Define Breast Cancer Liquid Biopsy-Based Biomarkers in Plasma Samples

“…Breast cancer (BC) ranks as the second most common cause of cancer-related deaths in women overall [1][2][3]. In 2023, BC was the most frequently diagnosed cancer in women, accounting for 31% worldwide [4,5], and the second in Spain for both sexes combined [6] To date, mammography screening is the only effective method for detecting the disease with a high true positive rate, decreasing mortality rates by 41%; nevertheless, it also has disadvantages, such as the cost-expensive resources, exposure to radiation, the breast compression and the final biopsy of the tissue [7][8][9].…”

Breast tumor classification using adam and optuna model optimization based on CNN architecture

“…Even after diagnosis, the challenges of breast cancer persist. At the end of 2020, approximately 7.8 million women had a history of breast cancer in the past five years [2], [3]. Breast cancer has reached the status of one of the most common cancers faced by women worldwide, and despite improvements in survival rates since the 1990s, thanks to early detection programs and the development of more effective medical therapies, this challenge remains a focus of attention.…”